Knight Therapeutics and Helsinn Expand Their Partnership: A New Era for ONICIT® IV in Mexico, Brazil, and Other LATAM Countries
Montreal, Canada, and Lugano, Switzerland, January 28, 2025 – In a groundbreaking move, Knight Therapeutics Inc. (TSX: GUD) and Helsinn Healthcare SA have announced an expansion of their existing relationship, leading to an exclusive license, distribution, and supply agreement for ONICIT® IV (palonosetron) in Mexico, Brazil, and other Latin American (LATAM) countries. ONICIT®, which is marketed as ALOXI® in Canada, is a critical anti-emetic medication used to prevent chemotherapy-induced nausea and vomiting.
Background on ONICIT® and its Role in Cancer Care
ONICIT®, a selective 5-HT3 receptor antagonist, has been a valuable tool in the fight against chemotherapy-induced nausea and vomiting for over two decades. Its proven efficacy and safety profile make it an essential component of supportive care for cancer patients undergoing chemotherapy. The medication’s ability to reduce the severity and frequency of chemotherapy-induced side effects significantly improves patients’ quality of life and their ability to complete their treatment courses.
The Collaboration Between Knight and Helsinn
Knight Therapeutics, a pan-American specialty pharmaceutical company, has been dedicated to improving the lives of patients in need by providing access to critical and complex medicines. Helsinn Healthcare SA, a global pharmaceutical company with a rich history of over forty-five years, has a strong focus on supportive care, oncology, and dermato-oncology. The companies’ shared commitment to patient care and medical innovation led them to form a strategic partnership in 2018, granting Helsinn exclusive distribution rights to several Knight products in Europe, Asia, and South America.
Impact on Patients in Mexico, Brazil, and Other LATAM Countries
The newly formed agreement between Knight and Helsinn will bring ONICIT® IV to patients in Mexico, Brazil, and other LATAM countries, ensuring they have access to this vital medication. The collaboration will not only improve the quality of care for cancer patients in these regions but also provide a more consistent and efficient supply chain. This partnership will contribute to better patient outcomes, as they will be able to undergo their chemotherapy treatments with fewer interruptions due to nausea and vomiting.
Global Implications of the Agreement
The expansion of the Knight-Helsinn partnership is a significant development in the global pharmaceutical industry. It highlights the importance of collaborative efforts between companies to ensure that patients worldwide have access to essential medications, regardless of their geographic location. This agreement also underscores the commitment of both companies to improving patient care and outcomes, ultimately making a difference in the lives of those battling cancer.
Conclusion
The collaboration between Knight Therapeutics and Helsinn continues to evolve, bringing ONICIT® IV to patients in Mexico, Brazil, and other Latin American countries. This exclusive license, distribution, and supply agreement will significantly impact the lives of cancer patients by providing them with access to this critical anti-emetic medication. The partnership also emphasizes the importance of global collaboration in the pharmaceutical industry, ensuring that patients around the world receive the care they need to fight their illnesses effectively.
- Knight Therapeutics and Helsinn expand their partnership.
- Exclusive license, distribution, and supply agreement for ONICIT® IV in Mexico, Brazil, and other LATAM countries.
- ONICIT® IV, a vital medication for preventing chemotherapy-induced nausea and vomiting.
- Collaboration to improve patient care and outcomes in LATAM countries.
- Global impact of the partnership in the pharmaceutical industry.
